CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that share certificates has been reported as lost by the shareholder of the Company22-12-2022
22-12-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares on Exercise of ESOPs15-12-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding the Loss of share certificates by the shareholders:- Mr.Banarsi Das and Mr.Subrahmanya Ravi M06-12-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended September 30, 2022. You are requested to take the above on record .27-11-2022
Buy Caplin Point Laboratories; target of Rs 955: ICICI Direct
ICICI Direct is bullish on Caplin Point Laboratories recommended buy rating on the stock with a target price of Rs 955 in its research report dated November 13, 2022.22-11-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of Transcript of Earnings Call Q2 - 2022-2318-11-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 201515-11-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement with respect to Q2 (2022-23) financial results published in the Financial Express and Maalai Malar14-11-2022
Q2FY23 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Caplin Point Laboratories announced Q2FY23 results: H1FY23 (Consolidated): Revenue for H1FY23 grew by 18.4% YoY to Rs 736 crore Gross margins for H1FY23 were 54.3% EBITDA for H1FY23 was Rs 238 crore; EBITDA margins at 32.4% H1FY23 PAT was at Rs 178 crore up 20.2% YoY Cash and cash surplus at Rs 778 crore as at end of September 2022; capex for H1FY23 is at Rs 53 crore; free cash flow for the period was Rs 88 crore Receivable days stood stable at 95 days as on Sept 22 Q2FY23 & H1FY23: Q2 FY23 Revenue at Rs 376 crore, up 20.4% YoY, as compared to Rs 312 crore in Q2FY22 PAT increased by 20.2% to Rs 178 crore in H1FY23 against Rs 148 crore in H1FY22 PAT for the quarter was at Rs 92 crore, up 19.8% as compared to Rs 77 crore in Q2FY22 Cash flow from operations at Rs 141 crore in H1FY23 as against Rs 337 crore for the whole year FY22 Basic EPS grew by 21% to Rs 23.31 in H1FY23 against Rs 19.28 in H1FY22 (not Annualized) With the depreciation of INR against USD, the exchange gain in H1FY23 is Rs 13.02 crore and for Q2 FY23 is Rs 6.70 crore as against the exchange gain of Rs 5.33 crore in H1FY22 and Rs 1.75 crore in Q2FY22 With a continued focus on cash flow, receivables stood at 95 days despite growth in sales Inventory stood at Rs 296 crore (including transit inventory of Rs.101 crore) on Sept 22 as against Rs 255 crore on June 22 Considering the extended transit time and with a focus on the need to keep Inventory closer to customers, the current level of inventory is likely to continue in H2 as well. The geographical breakup of sales: LATAM & ROW - 86%, US – 14% Result PDF14-11-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Outcome of Analyst call13-11-2022